These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 26121111)

  • 61. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
    Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
    Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Rischewski J; Sonnenberg S; Ayuk F; Tögel F; Schade U; Fiegel H; Erttmann R; Löliger C; Zander AR
    Bone Marrow Transplant; 2002 Apr; 29(8):683-9. PubMed ID: 12180114
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?
    Heelan F; Mallick R; Bryant A; Radhwi O; Atkins H; Huebsch L; Bredeson C; Allan D; Kekre N
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1298-1302. PubMed ID: 32165325
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.
    Tandra A; Covut F; Cooper B; Creger R; Brister L; McQuigg B; Caimi P; Malek E; Tomlinson B; Lazarus HM; Otegbeye F; Kolk M; de Lima M; Metheny L
    Leuk Lymphoma; 2018 Jul; 59(7):1644-1651. PubMed ID: 29199482
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms.
    Chalandon Y; Eikema DJ; Moiseev I; Ciceri F; Koster L; Vydra J; Passweg J; Rovira M; Ozcelik T; Gedde-Dahl T; Kröger N; Potter V; Yakoub-Agha I; Rambaldi A; Itälä-Remes M; Tanase A; Onida F; Gurnari C; Scheid C; Drozd-Sokolowska J; Raj K; McLornan DP; Robin M
    Blood Adv; 2024 Sep; 8(18):4792-4802. PubMed ID: 39008719
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.
    Messina G; Giaccone L; Festuccia M; Irrera G; Scortechini I; Sorasio R; Gigli F; Passera R; Cavattoni I; Filippi AR; Schianca FC; Pini M; Risitano AM; Selleri C; Levis A; Mordini N; Gallamini A; Pastano R; Casini M; Aglietta M; Montanari M; Console G; Boccadoro M; Ricardi U; Bruno B;
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1600-7. PubMed ID: 22484666
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
    Devillier R; Crocchiolo R; Castagna L; Fürst S; El Cheikh J; Faucher C; Prebet T; Etienne A; Chabannon C; Vey N; Esterni B; Blaise D
    Bone Marrow Transplant; 2012 May; 47(5):639-45. PubMed ID: 22307016
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.
    Rezvani AR; Kanate AS; Efron B; Chhabra S; Kohrt HE; Shizuru JA; Laport GG; Miklos DB; Benjamin JE; Johnston LJ; Arai S; Weng WK; Negrin RS; Strober S; Lowsky R
    Bone Marrow Transplant; 2015 Oct; 50(10):1286-92. PubMed ID: 26146806
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation.
    Kalra A; Williamson T; Daly A; Savoie ML; Stewart DA; Khan F; Storek J
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1654-1663. PubMed ID: 27246372
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
    Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
    Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation.
    Tian Z; Man Q; Yang Y; Guan H; Wang Y; Luo R; Wang J
    Ann Hematol; 2024 May; 103(5):1729-1736. PubMed ID: 38538977
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis.
    Zhou X; Cai Y; Yang J; Tong Y; Qiu H; Huang C; Zhou K; Xu X; Niu J; Xia X; Zhang Y; Shen C; Wei Y; Song X; Wan L
    Cell Transplant; 2022; 31():9636897221079739. PubMed ID: 35225024
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.
    Robin M; Raj K; Chevret S; Gauthier J; de Lavallade H; Michonneau D; McLornan D; Peffault de Latour R; Potter V; Kulasekararaj A; Sicre de Fontbrune F; Pagliuca A; Yakoub-Agha I; Socié G; Mufti GJ
    Eur J Haematol; 2018 Oct; 101(4):466-474. PubMed ID: 29714032
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.